Clinical Trials Browser

Recruiting × Neuroendocrine Tumors × lenvatinib × Clear all

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Phase 2 Recruiting

Neuroendocrine Tumors